BiondVax Pharmaceuticals Ltd. (NASDAQ:BVXV) – Stock analysts at Zacks Investment Research raised their Q4 2017 EPS estimates for shares of BiondVax Pharmaceuticals in a report released on Tuesday. Zacks Investment Research analyst D. Bautz now anticipates that the company will earn $0.00 per share for the quarter, up from their prior forecast of ($0.01).

Separately, ValuEngine cut shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.

BiondVax Pharmaceuticals (BVXV) traded down $0.21 on Thursday, hitting $4.99. 20,800 shares of the company traded hands, compared to its average volume of 43,768. BiondVax Pharmaceuticals has a twelve month low of $3.04 and a twelve month high of $10.75.

COPYRIGHT VIOLATION WARNING: “Q4 2017 EPS Estimates for BiondVax Pharmaceuticals Ltd. (BVXV) Boosted by Zacks Investment Research” was first published by Watch List News and is owned by of Watch List News. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at

BiondVax Pharmaceuticals Company Profile

BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.

Receive News & Ratings for BiondVax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals and related companies with's FREE daily email newsletter.